Ethical Tissue News
LIST OF PUBLICATIONS
Full papers:
2001
Choudry, G. A., Stewart, P. A., Double, J. A., Krul, M. R., Naylor, B., Flannigan, G. M., Shah, T. K., Brown, J. E., and Phillips, R. M. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer, 85: 1137-1146, 2001
2003
Gibson, P., Gill, J. H., Khan, P. A., Seargent, J. M., Martin, S. W., Batman, P. A., Griffith, J., Bradley, C., Double, J. A., Bibby, M. C., and Loadman, P. M. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther, 2: 527-534, 2003.
Puri R, Basu S, Loadman PM, Martin SW, Palit V, Lenaz G, Van Calken C, Naylor B, Phillips RM. Phase I clinical evaluation of intravesical EOquin (EO9) against superficial bladder cancer: Preliminary results (2003) Clinical Cancer Res 9, 62485 - 62495
2004
Basu, S., Brown, J. E., Flannigan, G. M., Gill, J. H., Loadman, P. M., Martin, S. W., Naylor, B., Puri, R., Scally, A. J., Seargent, J. M., Shah, T., and Phillips, R. M. NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. Int J Oncol, 25: 921-927, 2004.
Basu, S., Brown, J. E., Flannigan, G. M., Gill, J. H., Loadman, P. M., Martin, S. W., Naylor, B., Scally, A. J., Seargent, J. M., Shah, T., Puri, R., and Phillips, R. M. Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer, 109: 703-709, 2004.
Gill, J. H., Kirwan, I. G., Seargent, J. M., Martin, S. W., Tijani, S., Anikin, V. A., Mearns, A. J., Bibby, M. C., Anthoney, A., and Loadman, P. M. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia, 6: 777-785, 2004.
Phillips, R. M., Basu, S., Brown, J. E., Flannigan, G. M., Loadman, P. M., Martin, S. W., Naylor, B., Puri, R., and Shah, T. Detection of (NAD(P)H:Quinone oxidoreductase-1, EC 1.6.99.2) 609C-->T and 465C-->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP. Int J Oncol, 24: 1005-1010, 2004.
2005
Palit, V., Phillips, R. M., Puri, R., Shah, T., and Bibby, M. C. Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep, 14: 909-913, 2005.
Seargent, J. M., Loadman, P. M., Martin, S. W., Naylor, B., Bibby, M. C., and Gill, J. H. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology, 65: 815-820, 2005.
Gill JH, Kirwan IG, Seargent JM, Martin SW, Tijani S, Anikin VA, Mearns AJ, Bibby MC, Anthoney A, Loadman PM. MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas (2005) Neoplasia 6, 777 - 85
2006
Puri, R., Palit, V., Loadman, P. M., Flannigan, G. M., Shah, T., Choudry, G. A., Basu, S., Double, J. A., Lenaz, G., Chawla, S., Beer, M., Van Kalken, C., de Boer, R., Beijnen, J. H., Twelves, C., and Phillips, R. M. Phase I/II pilot study of intravesical EOquin (EO9) against superficial bladder cancer. J Urol, in press.
2007
Atkinson, J.M., Pennington, C.J., Martin, S.W., Anikin, V.A., Mearns, A.J., Loadman, P.M., Edwards, D.R. & Gill, J.H. MT-MMPS show differential expression in human non-small cell lung cancer compared to normal lung tissue: correlation of MMP -14 mRNA expression and proteolytic activity. EJC 43 (2007) 1764 - 1771
SUBMITTED PAPERS:
Jain,A. Puri, R., Beer, M., and Phillips, R.M. Two year response rate to intravesical EOquin in patients with recurrent superficial TCC. J Urol.
Gill, J.H., Basu, S., Seargent, J., Naylor, B., Puri, P., Shah, T., Flannigan, G.M., and Phillips, R.M. NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in Human Transitional Cell Carcinoma of the Bladder: Implications for the application of quinone based bioreductive drugs. Br J Urol.
BOOKS/BOOK CHAPTERS/REVIEW ARTICLES.
Basu, S., Martin, S. W., Phillips, R. M., and Puri, R. Obtaining archived pathological material for biomedical research. Lancet, 361: 1394, 2003.
Phillips, R. M. and Basu, S. Biological and clinical significance of polymorphisms in NAD(P)H:Quinone oxidoreductase-1 (NQO1). Curr Pharmacogenetics, 2: 75-83, 2004.
